Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
10:09am, Friday, 01'st Oct 2021
Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
08:55am, Friday, 01'st Oct 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA's ongoing review of the company'
Why Omeros Stock Is Plummeting This Week
08:36pm, Thursday, 30'th Sep 2021
The biotech stock was part of a larger Wall Street sell-off.
Omeros: The Prize Is Nigh (Again)
11:08pm, Monday, 13'th Sep 2021
Omeros: The Prize Is Nigh (Again)
Omeros Corporation's (OMER) CEO Greg Demopulos on Q2 2021 Results - Earnings Call Transcript
09:45pm, Monday, 09'th Aug 2021
Omeros Corporation's (OMER) CEO Greg Demopulos on Q2 2021 Results - Earnings Call Transcript
Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
07:13pm, Monday, 09'th Aug 2021
Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Omeros: Q2 Earnings Insights
04:58pm, Monday, 09'th Aug 2021
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to ($0.46), which beat the e
Omeros: PDUFA Delay Presents An Opportunity
10:45am, Saturday, 03'rd Jul 2021
Omeros has had its PDUFA delayed by three months. The reason is that the FDA needs additional time to review data it had asked for.
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
04:32pm, Thursday, 10'th Jun 2021
Omeros (OMER) announces initial results from a phase I study of OMS906.
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
08:45am, Thursday, 10'th Jun 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeuti
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
05:00pm, Wednesday, 09'th Jun 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
08:45am, Wednesday, 09'th Jun 2021
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeuti
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
08:01pm, Saturday, 05'th Jun 2021
New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
05:05am, Tuesday, 01'st Jun 2021
NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised t
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients
06:02pm, Monday, 31'st May 2021
Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.
